The revised Technical Document on Harmonization of Analysis and Reporting of recombinant Erythropoietins (i.e. Epoetins) and Analogues (e.g. Darbepoetin, Pegserpoetin, Peginesatide, EPO-Fc) by Electrophoretic Techniques (TD EPO) has been approved by WADA’s Executive Committee and will come into force on March 1, 2013.
As part of WADA's ongoing efforts to enhance worldwide anti-doping activities under the World Anti-Doping Code, TD EPO undergoes periodic revision to reflect recent scientific and technological advances in the performance of anti-doping tests and the reporting of test results.
The revision process for this Technical Document was conducted by WADA's Laboratory Expert Group in 2012, and carried out in consultation with WADA’s stakeholders.
TD EPO is a mandatory complementary document to the International Standard for Laboratories and provides specific technical recommendations to WADA accredited laboratories.
To view the technical document TD2013 EPO, click here.
To view the Summary of modifications of TD2013 EPO, click here.